Readoutin 104d
Fujian Shengdi Pharmaceutical Co., Ltd. — HRS9531 injection
Phase 3 primary completion: A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity.
- Date
- Mar 2027
- Type
- Readout
- Indication
- Obesity